Niagen Bioscience, Inc. — Director's Dealing 2017

Dec 26, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ChromaDex Corp. (CDXC)
CIK: 0001386570
Period of Report: 2017-12-21

Reporting Person: Jaksch Frank L Jr (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-12-21	Common Stock	M	58400	$4.50	Acquired	259957	Direct
2017-12-21	Common Stock	S	58400	$6.19	Disposed	201557	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-12-21	Employee Stock Options (right to buy)	$4.50	M	58400	Disposed	2018-04-21	Common Stock (58400)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	2075052	Indirect

Footnotes

F1: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted on November 17, 2017. The options exercised and sold were scheduled to expire on April 21, 2018 and Mr. Jaksch sold the shares so that the proceeds can be used to cover the exercise payment and applicable withholding taxes due.